Symbol="ALGS"
AssetType="Common Stock"
Name="Aligos TherapeuticsÂ Inc"
Description="Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on developing novel therapies to address unmet medical needs in viral and liver diseases. The company is headquartered in South San Francisco, California."
CIK="1799448"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)"
Address="ONE CORPORATE DR., 2ND FLOOR, SOUTH SAN FRANCISCO, CA, US"
FiscalYearEnd="December"
LatestQuarter="2023-06-30"
MarketCapitalization="38646100"
EBITDA="-82771000"
PERatio="None"
PEGRatio="None"
BookValue="1.601"
DividendPerShare="0"
DividendYield="0"
EPS="-1.89"
RevenuePerShareTTM="0.402"
ProfitMargin="0"
OperatingMarginTTM="-4.909"
ReturnOnAssetsTTM="-0.367"
ReturnOnEquityTTM="-0.796"
RevenueTTM="17252000"
GrossProfitTTM="-71170000"
DilutedEPSTTM="-1.89"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="0.865"
AnalystTargetPrice="4"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="3.788"
PriceToBookRatio="0.351"
EVToRevenue="69.48"
EVToEBITDA="0.793"
Beta="2.211"
num_52WeekHigh="2.41"
num_52WeekLow="0.84"
num_50DayMovingAverage="0.974"
num_200DayMovingAverage="1.172"
SharesOutstanding="39847800"
DividendDate="None"
ExDividendDate="None"
symbol="ALGS"
open="0.90"
high="0.90"
low="0.85"
price="0.86"
volume="92414.00"
latest_trading_day="2023-08-18"
previous_close="0.90"
change="-0.04"
change_percent="-4.4444%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="80"
trend_strength="Absent or Weak Trend"
buying_signal="Strong Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="20"
Volume_recent_avg="173808"
Change_recent_avg="-0.01"
Delta_recent_avg="0.09"
Variance_recent_avg="0.04"
Change_ratio_recent_avg="-1.11"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="20"
Aroon_momentum_negative="80"
image_negative_thumbnail_id_1="162"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0014.jpeg"
image_negative_thumbnail_id_2="1147"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0180.jpeg"
image_neutral_thumbnail_id_1="532"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0067.jpeg"
image_neutral_thumbnail_id_2="576"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0023.jpeg"
image_positive_thumbnail_id_1="975"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0137.jpeg"
image_positive_thumbnail_id_2="965"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0127.jpeg"
image_professor_thumbnail_id_1="1180"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0014.jpeg"
image_professor_thumbnail_id_2="1196"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0030.jpeg"
